(1S,2S)-反式-1,2-环戊烷二胺二盐酸盐 | 477873-22-6

• 物质功能分类: 化学试剂 - 有机试剂 - 多胺
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (1S,2S)-反式-1,2-环戊烷二胺二盐酸盐
• 英文名称: (1S,2S)-trans-1,2-Cyclopentanediamine dihydrochloride
• 英文别名: (1S,2S)-cyclopentane-1,2-diamine;dihydrochloride
• CAS: 477873-22-6
• 化学式: C5H14Cl2N2
• 分子量: 173.08
• InChiKey: VZCLGIZICFQJBX-RSLHMRQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.67
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  4
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• WGK Germany：
  3

文献信息

• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110064695A1

  公开（公告）日：2011-03-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： 这些化合物抑制RNA含病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物，包括含有这些化合物的药物组合物，以及用于治疗或预防受试者需要此类治疗的病毒（特别是HCV）感染的方法。
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
  申请人：Ahmed Gulzar

  公开号：US20090221555A1

  公开（公告）日：2009-09-03

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供公式I或II化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。公式I或II化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。
• Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
  申请人：Ahmed Gulzar

  公开号：US20120165519A1

  公开（公告）日：2012-06-28

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了式I或II的化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。式I或II的化合物具有ALK和/或c-Met抑制活性，并可用于治疗增生性疾病。
• Pharmaceutical waste disposal assembly
  申请人：Stryker Corporation

  公开号：US10086416B2

  公开（公告）日：2018-10-02

  A pharmaceutical waste disposal assembly (10) for disposing of raw pharmaceutical waste includes a receiver body (19) and a first reaction agent (287). The receiver body (19) is configured to receive the pharmaceutical waste. The receiver body (19) includes a body interior wall (921A) that defines a body interior (921B). The first reaction agent (287) is positioned within the body interior (921B) so that the first reaction agent (287) contacts the body interior wall (921A) prior to receiving the pharmaceutical waste. The first reaction agent (287) chemically reacts with the pharmaceutical waste so that the pharmaceutical waste is rendered unrecoverable. The first reaction agent (287) can include at least one of a denaturant and a deterrent. Additionally, the first reaction agent (287) can include activated charcoal.

  用于处置未加工药物废物的药物废物处置组件 (10) 包括一个接收体 (19) 和一个第一反应剂 (287)。接收器主体（19）被配置为接收医药废物。接收器主体 (19) 包括限定主体内部 (921B) 的主体内壁 (921A)。第一反应剂 (287) 位于主体内部 (921B) 中，以便第一反应剂 (287) 在接收药物废料之前接触主体内壁 (921A)。第一反应剂 (287) 与药物废物发生化学反应，使药物废物无法回收。第一反应剂 (287) 可以包括变性剂和阻遏剂中的至少一种。此外，第一反应剂（287）还可以包括活性炭。
• Waste disposal system and waste receiver for receiving and disposing of pharmaceutical waste material
  申请人：Stryker Corporation

  公开号：US10940513B2

  公开（公告）日：2021-03-09

  A waste disposal system with a waste receiver for receiving pharmaceutical waste material. A locking assembly is secured to a fixed surface and actuated from a locked configuration to an unlocked configuration. A lock cylinder of the locking assembly may extend forward of a front wall of a receiver body of the waste receiver to engage a locking feature of the cover in the locked configuration. A cover retention feature may prevent axial decoupling of the cover from the receiver body. An engagement feature is moved to be disengaged from the receiver body, and the receiver body is moved away from the fixed surface to disengage the locking assembly from the cover. The cover is decoupled from the cover retention feature, and coupled with the receiver body to seal the pharmaceutical waste material. The locking assembly may be removed from a lock passageway for disposal of the waste receiver.

  一种废物处理系统，带有一个用于接收药物废料的废物接收器。一个锁定组件固定在一个固定表面上，并从锁定配置驱动到解锁配置。锁定组件的锁芯可从废物接收器的接收器主体的前壁向前延伸，以便在锁定配置中与盖子的锁定功能相啮合。盖子固定特征可防止盖子与接收器本体的轴向脱钩。移动啮合特征，使其与接收器本体脱离，接收器本体远离固定表面，使锁定组件与盖子脱离。盖子与盖子固定特征脱钩，并与接收器本体耦合，以密封药物废料。锁定组件可从锁定通道中取出，以便对废物接收器进行处置。